NCT Neuro Master Match - N²M² (NOA-20) (N²M²)
Umbrella Protocol for Phase I/IIa Trials of Molecularly Matched Targeted Therapies Plus Radiotherapy in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation: NCT Neuro Master Match - N²M² (NOA-20)
Sponsor: German Cancer Aid
A PHASE1/PHASE2 clinical study on Glioblastoma, Adult, this trial is completed. The trial is conducted by German Cancer Aid and has accumulated 8 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Jun 2022 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Mar 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- German Cancer Aid
- German Cancer Research Center
- National Center for Tumor Diseases, Heidelberg
- University Hospital Heidelberg
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berlin, Germany , Bochum, Germany , Bonn, Germany , Cologne, Germany , Dresden, Germany , Essen, Germany , Frankfurt am Main, Germany , Heidelberg, Germany , Homburg, Germany , Mainz, Germany and 3 more locations